Hyperventilation Effects on Bodily Self-Consciousness

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-55
SponsorUniversity of Fribourg

About this trial

This study examines how voluntary fast, deep breathing (hyperventilation) affects the way healthy adults perceive their own body. Participants wear a virtual-reality (VR) headset and see a virtual body; a glowing halo around it either pulses exactly in time with their own breathing or is time-shifted. During the study, breathing, heart activity, blood-oxygen level, the carbon-dioxide content of exhaled air, and brain activity (EEG, measured non-invasively from the scalp) are recorded continuously, and participants complete questionnaires about their experience.

The aim is to understand whether and how altered breathing changes the interplay between what people see and what they feel inside their body, and thereby the sense of being located within one's own body. The study uses a 2×2 within-subjects design crossing Breathing (normal vs. hyperventilation) with Visual synchrony (synchronous vs. asynchronous), with the asynchronous and normal-breathing conditions serving as within-subject controls.

No medication is administered and no medical device is being tested; the instruments used serve only for monitoring and measurement. Participation involves a screening visit (including a short, \~5-minute guided-hyperventilation tolerance test) and an experimental visit.

Eligibility criteria

Qualifiers

Healthy adult aged 18-55 years

Able to provide written informed consent

Normal or corrected-to-normal vision

Sufficient German or English to follow instructions and complete questionnaires

Disqualifiers

Cardiovascular or cerebrovascular disease posing a risk during hyperventilation (e.g., myocardial infarction or stroke within 12 months, significant/unstable cardiac disease, heart failure, uncontrolled/severe hypertension, aneurysm, Moyamoya)

Respiratory disease (asthma, COPD, restrictive lung disease, pulmonary fibrosis, recent severe lung infection, dyspnoea at rest)

Haematological disease (sickle cell disease or trait, severe anaemia)

Neurological disease (epilepsy or seizures, severe/recurrent migraine, neurodegenerative disorder)

Trial design

Treatments tested in this trial

  • Voluntary hyperventilation (guided paced breathing)
  • Normal spontaneous breathing (within-subject control)
  • Synchronous respiratory-visual VR feedback
  • Asynchronous respiratory-visual VR feedback

Treatment groups

35 Participants
are divided into 2 treatment groups

Sponsors and collaborators